Imaging and biodistribution of radiolabeled SP90 peptide in BT-483 tumor bearing mice

Appl Radiat Isot. 2020 Jul:161:109162. doi: 10.1016/j.apradiso.2020.109162. Epub 2020 Apr 2.

Abstract

The objective of this study was to evaluate radiolabeled DOTA-SP90 as a radiotracer for breast cancer. The in vitro competition assay showed that radiolabeled DOTA-SP90 had significant binding affinity to BT-483 cancer cells. Biodistribution, nanoSPECT/CT and nanoPET/CT imaging results indicated that radiolabeled DOTA-SP90 can accumulate in tumors. In addition, radiolabeled DOTA-SP90 peptides can also detect metastatic tumors. Therefore, radiolabeled SP90 peptide may provide the potential capability as diagnostic agent for breast cancer patients.

Keywords: BT-483; DOTA-SP90; nanoPET/CT; nanoSPECT/CT.

MeSH terms

  • Animals
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / metabolism
  • Cell Line, Tumor
  • Female
  • Gallium Radioisotopes / pharmacokinetics*
  • Heterocyclic Compounds, 1-Ring / metabolism
  • Humans
  • Indium Radioisotopes / pharmacokinetics*
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Multimodal Imaging
  • Oligopeptides / chemistry
  • Oligopeptides / pharmacokinetics*
  • Radiopharmaceuticals / chemistry
  • Radiopharmaceuticals / pharmacokinetics*
  • Tissue Distribution
  • Xenograft Model Antitumor Assays

Substances

  • Gallium Radioisotopes
  • Heterocyclic Compounds, 1-Ring
  • Indium Radioisotopes
  • Oligopeptides
  • Radiopharmaceuticals
  • SP90 peptide
  • 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid